Empagliflozin: a new strategy for nephroprotection in diabetes
Empagliflozin, an inhibitor of sodium–glucose symporter type 2 (SGLT2), is a new class of antidiabetic agents with numerous pleiotropic effects. The review summarises data on the influence of empagliflozin on the structural and functional changes in the kidneys of the models of diabetes me...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | article |
| Langue: | EN RU |
| Publié: |
Endocrinology Research Centre
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/13c2256433f64e878a433cb9f5179a47 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|